©1996-2019. All Rights Reserved. Online Journal of Bioinformatics . You may not store these pages in any form except for your own personal use. All other usage or distribution is illegal under international copyright treaties. Permission to use any of these pages in any other way besides the before mentioned must be gained in writing from the publisher. This article is exclusively copyrighted in its entirety to OJB publications. This article may be copied once but may not be, reproduced or re-transmitted without the express permission of the editors. This journal satisfies the refereeing requirements (DEST) for the Higher Education Research Data Collection (Australia). Linking:To link to this page or any pages linking to this page you must link directly to this page only here rather than put up your own page.
Online Journal of Bioinformatics ©
Volume 11 (1): 128-144, 2010
Structural model of the mammalian target of rapamycin (mTOR) kinase domain
Anne Tobak1, Sonia Arora2, and William J. Welsh1*
1 Department of Pharmacology, University of Medicine & Dentistry of New Jersey-Robert Wood Johnson Medical School (UMDNJ-WJMS) & Informatics Institute of UMDNJ, 675 Hoes Lane, Piscataway, NJ 08854, USA, 2 NJ Center for Science, Technology and Mathematics, Kean University, 1000 Morris Avenue, Union, NJ 07083, USA
Tobak A, Arora S, Welsh WJ., Structural model of the mammalian target of rapamycin (mTOR) kinase domain, Onl J Bioinform., 11 (1):128-144, 2010. The mammalian target of rapamycin (mTOR) is a serine/threonine kinase involved in the regulation of protein translation and cell proliferation. Based on signals received from nutrition, growth factors and insulin, mTOR controls cell growth accordingly and is therefore a key target for anticancer therapeutics and numerous other clinically relevant applications. Two regions of interest are the FRB domain, where mTORís natural ligand rapamycin binds when in complex with FKBP12, and the ATP-binding site located within the kinase domain. Some cancer cells have shown resistance to the inhibitory effects of rapamycin and its analogues, while other known kinase domain inhibitors generally lack stability and specificity. Clearly, there is a need for kinase domain-targeted mTOR inhibitors as potential therapeutics. Efforts to discover mTOR kinase-targeted inhibitors using structure-based design approaches have been impeded by the absence of a high-resolution x-ray crystal structure of the mTOR kinase domain. Here we describe the construction of a computational structural model of the mTOR kinase domain. Computational docking of ATP as well as known mTOR kinase inhibitors wortmannin and LY294002 into mTORís putative ligand binding pocket reveals several residues that might be critical for tight binding and inhibitory activity.
Keywords: mTOR, homology modeling, docking, wortmannin, LY294002, PI3K, kinase domain